Senti Biosciences, Inc. (SNTI)
| Previous close | 0.2990 |
| Open | 0.2921 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.2921 - 0.2921 |
| 52-week range | 0.2700 - 1.1000 |
| Volume | |
| Avg. volume | 81,877 |
| Market cap | 13.349M |
| Beta (5Y monthly) | 2.97 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.8800 |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.00 |
GlobeNewswireSenti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
– IND for SENTI-202, a potential first-in-class logic-gated treatment for AML, cleared by the U.S. FDA; First patient dosing anticipated in the second quarter of 2024 – – Cash and anticipated receivables from GeneFab transaction expected to fund operations into the first quarter of 2025 – SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and gene therapies
- GlobeNewswire
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
– Strategic resource allocation to focus investment on clinical development of SENTI-202 and SENTI-301A partnership in China; interim data from Phase 1 clinical trial of SENTI-202 expected in 2H 2024 – – Anticipated cost savings, which includes an approximately 37% reduction in workforce, expected to extend cash runway into 1Q 2025 – SOUTH SAN FRANCISCO, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical stage biotechnology
ZacksSenti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate
The FDA clears Senti Bio's (SNTI) investigational new drug application for SENTI-202 for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia. Stock rises.
